Trusted by:
Moffitt Cancer Center researchers, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of acquired drug resistance and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.
Researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance. They are hopeful that the discovery may lead to therapies that are tailored to individual patients with ovarian cancer.
A new and better understanding of blood vessel growth and vascular development (angiogenesis) in cancer has been made possible by research by a team of scientists from Moffitt Cancer Center, the University of Florida, Harvard University, Yale University and the Children鈥檚 Hospital of Los Angeles.
Researchers have found that tumor cell resistance to a specific cancer immunotherapy designed to kill cancer cells can be blamed on a mechanism that involves the production of a free radical peroxynitrite (PNT) that causes resistance to therapeutic cancer-killing cells.
According to a researcher at Moffitt Cancer Center in Tampa, Fla., and her colleagues in the Netherlands, earlier circumcision of males in South Africa may be a positive step in slowing the spread of both HIV and the human papillomavirus (HPV). Their commentary and data were published in a recent issue of the British medical journal The Lancet Infectious Diseases.
Publishing in the current issue of The Journal of Biological Chemistry, Moffitt Cancer Center researchers have discovered additional mechanisms of 鈥淎kt鈥� activation and suggest a component of that activation mechanism 鈥� inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) 鈥� could be targeted as a therapeutic intervention for treating cancer.
Assessing the quality of life experienced by cancer survivors is becoming increasingly important, say Moffitt Cancer Center researchers. Such an assessment has a number of important applications when doing research on cancer survivorship, but just how to measure quality of life for cancer survivors is still being developed.
Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, Moffitt Cancer Center researchers have tested a process by which T regulatory cells (Tregs) can be 鈥渆xpanded鈥� to help prevent GVHD.
Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center and colleagues at Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy. A tool of great promise comes from the world of nanomedicine 鈥� where tiny drug delivery systems are measured in the billionths of meters and are being designed to deliver targeted therapies.
A protein called 鈥渇ascin鈥� appears to play a critical transformation role in TGF beta mediated tumor metastasis, say researchers at Moffitt Cancer Center, who published a study in a recent issue of the Journal of Biological Chemistry.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right